Healthcare

CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]

Newsmakers

NexTech (OTC: NEXCF) Receives New 2020 Contract from Walther Arms Inc., Manufacturer of James Bond’s PPK

NEW YORK and TORONTO, Feb. 12, 2020  — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for e-commerce and AR learning applications, has received a new order from Walther Arms, most famous as the […]

Newsmakers

Former EVP, Head of Universal Music Group and Brands-USA Joins Advisory Board of Imagination Park Technologies (OTC: IPNFF)

Vancouver, CANADA – – February 11 , 2020 – Imagination Park Technologies Inc. (CSE: IP)(OTC: IPNFF) today announced that Mike Tunnicliffe has joined the Company as a Senior Advisor to the CEO. Mr. Tunnicliffe previously served […]

Newsmakers

CytoDyn (OTC: CYDY) Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers

VANCOUVER, Washington, Feb. 06, 2020– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it […]

Healthcare

CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Healthcare

CytoDyn (OTC: CYDY) Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition

Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same […]

Newsmakers

NexTech (OTC: NEXCF) Signs Partner Agreement with Jolokia Bringing AR to the Global Learning and Development Industry

AR and Interactive Video combine to create world’s most compelling training platform NEW YORK and TORONTO, Jan. 28, 2020– NexTech AR Solutions (the “Company” or “NexTech”) (otcqb:NEXCF) (NTAR)(N29) NexTech AR Solutions, the industry leader in […]

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab Under Evaluation for Potential Treatment of Coronavirus

CytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV) VANCOUVER, Washington, Jan. 28, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology […]

Healthcare

CytoDyn (OTC: CYDY) Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure

VANCOUVER, Washington, Jan 27, 2020 — The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn has […]